Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: A novel migraine model

Brain Research

Volumn 775, Issue 1-2, 1997, Pages 189-192

  McCall, Robert B ^a  

^a PFIZER INC   (United States)

Author keywords

Blood flow; Migraine; Nucleus trigeminal caudalis; Sumatriptan

Indexed keywords

CHLORALOSE; SUMATRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; CAT; CONTROLLED STUDY; DRUG EFFICACY; ELECTROSTIMULATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LASER DOPPLER FLOWMETRY; MALE; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION;

ANIMALS; CATS; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; FEMALE; MALE; MIGRAINE DISORDERS; REGIONAL BLOOD FLOW; SEROTONIN AGONISTS; SUMATRIPTAN; TRIGEMINAL GANGLION; TRIGEMINAL NUCLEUS, SPINAL;

EID: 0031460368     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00952-9     Document Type: Article

References (10)

1. Buzzi G.B., Moskowitz M.A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol. 99:1990;202-206.
2. 1-like agonists in the treatment of migraine. J. Neurol. 238:1991;S57-S61.
3. G.F. Gebhart, Visceral pain mechanisms: relevance to migraine, in: J. Olesen, M.A. Moskowitz (Eds.), Experimental Headache Models, Lippincott-Raven, Philadelphia, PA, 1995, pp. 39-47.
4. Humphrey P.P.A., Feniuk W., Marriott A.S., Tanner R.J.N., Jackson M.R., Tucker M.L. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol. 31:1991;282-290.
5. Kaube H., Hoskin K.L., Goadsby P.J. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br. J. Pharmacol. 109:1993;788-792.
6. 1Dβ receptors. Circulation. 90:1994;1141-1153.
7. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. 13:1992;307-311.
8. Rebeck G.W., Maynard K.I., Hyman B., Moskowitz M.A. Selective 5-HT1Da receptor gene expression in trigeminal ganglia: implications for anti-migraine drug development. Proc. Natl. Acad. Sci. USA. 91:1994;3666.
9. Tansey M.J.B., Pilgrim A.J., Lloyd K. Sumatriptan in the acute treatment of migraine. J. Neurol. Sci. 114:1993;109-116.
10. 1 antagonist on the consequences of trigeminal activation in the rat, in: J. Olesen, M.A. Moskowitz (Eds.), Experimental Headache Models, Lippincott-Raven, Philadelphia, PA, 1995, pp. 83-88.